MX365216B - Forma de dosificacion por via oral de difenhidramina de disolucion rapida. - Google Patents
Forma de dosificacion por via oral de difenhidramina de disolucion rapida.Info
- Publication number
- MX365216B MX365216B MX2018007440A MX2018007440A MX365216B MX 365216 B MX365216 B MX 365216B MX 2018007440 A MX2018007440 A MX 2018007440A MX 2018007440 A MX2018007440 A MX 2018007440A MX 365216 B MX365216 B MX 365216B
- Authority
- MX
- Mexico
- Prior art keywords
- dosage form
- oral dosage
- quick dissolving
- diphenhydramine
- diphenhydramine oral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Una forma de dosificación por vía oral para suministrar difenhidramina a través de la mucosa sublingual o bucal. La forma de dosificación por vía oral puede contener difenhidramina, o una sal farmacéuticamente aceptable de esta, un potenciador de la permeabilidad y un agente regulador. El agente regulador puede lograr un pH de aproximadamente 7.0 a aproximadamente 8.0. La difenhidramina puede disolverse totalmente en aproximadamente 2 minutos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/973,759 US9855227B2 (en) | 2015-12-18 | 2015-12-18 | Quick dissolving diphenhydramine oral dosage form |
PCT/US2016/064367 WO2017105852A1 (en) | 2015-12-18 | 2016-12-01 | Quick dissolving diphenhydramine oral dosage form |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2018007440A MX2018007440A (es) | 2018-11-09 |
MX365216B true MX365216B (es) | 2019-05-27 |
Family
ID=57570599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018007440A MX365216B (es) | 2015-12-18 | 2016-12-01 | Forma de dosificacion por via oral de difenhidramina de disolucion rapida. |
Country Status (5)
Country | Link |
---|---|
US (3) | US9855227B2 (es) |
EP (1) | EP3389625B1 (es) |
CN (1) | CN108366961B (es) |
MX (1) | MX365216B (es) |
WO (1) | WO2017105852A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9855227B2 (en) | 2015-12-18 | 2018-01-02 | The Procter & Gamble Company | Quick dissolving diphenhydramine oral dosage form |
EP3398590A1 (de) * | 2017-05-02 | 2018-11-07 | Stada Arzneimittel Ag | Schmelztablette, enthaltend ein h1-antihistaminika |
US20210378916A1 (en) * | 2018-10-19 | 2021-12-09 | Shalon Ventures Research Llc | Personalized drug dose dispenser and method |
WO2020243538A1 (en) * | 2019-05-31 | 2020-12-03 | Primo Pharmatech Llc | Unit dosage form for transmucosal drug delivery of an active pharmaceutical ingredient |
CN114788817A (zh) * | 2021-01-25 | 2022-07-26 | 南京宁丹新药技术有限公司 | 苯海拉明药物组合物 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4866046A (en) | 1988-05-31 | 1989-09-12 | Top Laboratories, Inc. | Low-dosage sublingual aspirin |
US6200604B1 (en) | 1998-03-27 | 2001-03-13 | Cima Labs Inc. | Sublingual buccal effervescent |
CA2348452A1 (en) | 1998-10-27 | 2000-05-04 | Biovail Technologies Ltd. | Microparticles containing peg and/or peg glyceryl esters |
CA2311734C (en) | 2000-04-12 | 2011-03-08 | Bristol-Myers Squibb Company | Flash-melt oral dosage formulation |
AU2001261744A1 (en) | 2000-05-19 | 2001-12-03 | Npd Llc | Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements |
AU2003241322A1 (en) | 2002-04-30 | 2003-11-17 | Npd Llc | Multi-phasic delivery via transmucosal absorption of antiemetic medicaments |
EP1444976A1 (en) | 2003-02-10 | 2004-08-11 | Novadel Pharma Inc. | Buccal, polar and non-polar spray or capsule |
US20060051413A1 (en) | 2004-09-08 | 2006-03-09 | Chow Sing S M | Method of enhancing absorptions of transmucosal administration formulations |
CN101102748A (zh) * | 2004-12-23 | 2008-01-09 | 麦克内尔-Ppc股份有限公司 | 具有感觉提示剂的在口中分裂的药物组合物 |
EP2767163A1 (en) | 2005-02-17 | 2014-08-20 | Abbott Laboratories | Transmucosal administration of drug compositions for treating and preventing disorders in animals |
US20070134493A1 (en) | 2005-12-08 | 2007-06-14 | Kanji Meghpara | Compositions and capsules with stable hydrophilic layers |
US20100086495A1 (en) | 2007-02-15 | 2010-04-08 | Derma-Young Ltd. | Compositions and methods for enhancing transmucosal delivery |
CA2702614A1 (en) | 2007-10-19 | 2009-04-23 | Innozen, Inc. | Composition for administering an active ingredient and method for making and using the same |
WO2009076361A1 (en) * | 2007-12-10 | 2009-06-18 | Eurand, Inc. | Orally disintegrating tablets comprising diphenhydramine |
US20090246256A1 (en) | 2008-03-27 | 2009-10-01 | Al-Ghananeem Abeer M | Compositions and Methods for Transmucosal Delivery of Lofexidine |
US8138169B2 (en) | 2008-04-11 | 2012-03-20 | Comgenrx, Inc. | Combination therapy for bipolar disorder |
US20090263476A1 (en) | 2008-04-16 | 2009-10-22 | Jobdevairakkam Christopher N | Composition of Rapid Disintegrating Direct Compression Buccal Tablet |
JP5580815B2 (ja) | 2008-06-19 | 2014-08-27 | ユニバーシティ・オブ・ジ・ウィトウォーターズランド・ヨハネスブルク | 経粘膜デリバリーシステム |
WO2012170883A1 (en) | 2011-06-09 | 2012-12-13 | Discovery Pharma Consulting, Llc | Antihistamines combined with dietary supplements for improved health |
CA2853117C (en) | 2011-10-25 | 2018-08-07 | Expermed S.A. | Sublingual pharmaceutical composition containing an antihistamine agent and method for the preparation thereof |
CN102488680B (zh) * | 2011-12-21 | 2012-12-26 | 西南大学 | 布洛芬苯海拉明分散片及其制备方法 |
CN102488681B (zh) | 2011-12-21 | 2013-03-13 | 西南大学 | 布洛芬苯海拉明口腔崩解片及其制备方法 |
CN102440973B (zh) * | 2011-12-21 | 2013-06-12 | 西南大学 | 枸橼酸苯海拉明口腔崩解片及其制备方法 |
US9511028B2 (en) | 2012-05-01 | 2016-12-06 | Johnson & Johnson Consumer Inc. | Orally disintegrating tablet |
ES2908977T3 (es) | 2013-06-03 | 2022-05-04 | Mcneil Ab | Forma de dosificación farmacéutica sólida para liberar en la cavidad oral al menos dos ingredientes farmacéuticos activos |
US9855227B2 (en) * | 2015-12-18 | 2018-01-02 | The Procter & Gamble Company | Quick dissolving diphenhydramine oral dosage form |
-
2015
- 2015-12-18 US US14/973,759 patent/US9855227B2/en active Active
-
2016
- 2016-12-01 CN CN201680074512.XA patent/CN108366961B/zh not_active Expired - Fee Related
- 2016-12-01 WO PCT/US2016/064367 patent/WO2017105852A1/en active Application Filing
- 2016-12-01 EP EP16813272.8A patent/EP3389625B1/en active Active
- 2016-12-01 MX MX2018007440A patent/MX365216B/es active IP Right Grant
-
2017
- 2017-11-28 US US15/823,636 patent/US10085954B2/en active Active
-
2018
- 2018-08-30 US US16/117,375 patent/US10624845B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN108366961B (zh) | 2022-02-18 |
CN108366961A (zh) | 2018-08-03 |
MX2018007440A (es) | 2018-11-09 |
US20190015321A1 (en) | 2019-01-17 |
US20170172948A1 (en) | 2017-06-22 |
EP3389625B1 (en) | 2021-11-17 |
WO2017105852A1 (en) | 2017-06-22 |
EP3389625A1 (en) | 2018-10-24 |
US10624845B2 (en) | 2020-04-21 |
US10085954B2 (en) | 2018-10-02 |
US9855227B2 (en) | 2018-01-02 |
US20180078514A1 (en) | 2018-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX365216B (es) | Forma de dosificacion por via oral de difenhidramina de disolucion rapida. | |
MY187047A (en) | Selective pyy compounds and uses thereof | |
NZ762034A (en) | Human plasma kallikrein inhibitors | |
PH12018502109A1 (en) | Medicine obtained by combining fxr agonist and arb | |
CL2017003066A1 (es) | Composiciones de carbonato de calcio amorfo para administración mediante inhalación, sublingual o bucal | |
IN2013MU03583A (es) | ||
PH12017502376B1 (en) | Oral solid formulation containing irinotecan and method of preparing the same | |
MX2021008432A (es) | Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal. | |
PH12016502246B1 (en) | Carboxamide derivatives | |
ZA202200511B (en) | Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis | |
EA201892842A1 (ru) | Фармацевтические композиции, включающие сафинамид | |
IL269884B1 (en) | Gamkaban its accepted pharmaceutical salts, their compositions and methods of their use | |
JO3435B1 (ar) | تركيبة دوائية صلبة تحتوي على أملوديبن ولوسارتان | |
WO2016015798A9 (en) | Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population | |
TR201721700A2 (tr) | Saksagli̇pti̇ni̇n ağizda dağilan formülasyonlari | |
PH12016502059A1 (en) | Fast dissolving granulate | |
IN2014MU00043A (es) | ||
IN2013MU03428A (es) | ||
PH12016502527A1 (en) | Stabilized desmopressin | |
TR201717703A2 (tr) | Api̇ksaban formülasyonlari | |
EA201991007A1 (ru) | Твердые фармацевтические композиции на основе гидрохлорида луразидона для перорального применения | |
TR201713326A2 (tr) | Rivaroksaban İçeren Formülasyonlar İçin Üretim Yöntemi | |
TR201713325A2 (tr) | Ri̇varoksaban i̇çeren formülasyonlar i̇çi̇n üreti̇m yöntemi̇ | |
IN2014MU01179A (es) | ||
GB2541348A (en) | Clopidogrel for use in the treatment of benign prostatic hyperplasia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |